Physician profile
Barbara Hurst
NPI 1205973070
$2,847.61
in general payments reported to CMS, 2019-2025
37 companies · $16.16 in 2025
The $16.16 reported for 2025 was less than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $361 · 2021: $592 · 2022: $870 · 2023: $364 · 2024: $168 · 2025: $16.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $529 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $528.75 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $415.83 | 2022 | |
| Astellas Pharma US INC | $288.08 | 2019-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $243.44 | 2019-2023 | |
| Boston Scientific Corporation | $239.01 | 2019-2025 | Solyx Sis System, General - Pain Management |
| Hologic Sales and Service, LLC | $140.46 | 2020-2023 | Aptima |
| Duchesnay USA Incorporated | $134.19 | 2019 | |
| Channel Medsystems, INC. | $103.49 | 2022 | |
| Allergan, INC. | $97.26 | 2019-2020 | |
| Evofem Biosciences, INC. | $97.09 | 2021 | |
| Daiichi Sankyo INC. | $95.47 | 2019-2022 | |
| Therapeuticsmd, INC. | $90.48 | 2019-2021 | |
| Exeltis, USA INC. | $90.44 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.48 | 2019-2022 | |
| Pfizer INC. | $76.80 | 2019-2023 | |
| Ascend Therapeutics US, LLC | $61.84 | 2022-2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $56.27 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $51.58 | 2021-2023 | |
| Becton, Dickinson and Company | $51.32 | 2021-2022 | |
| Genmab U.S., INC. | $41.85 | 2023-2024 | Tivdak |
| C. R. Bard, INC. & Subsidiaries | $40.09 | 2023 | Bd Onclarity |
| Avion Pharmaceuticals | $39.95 | 2021-2022 | |
| Organon LLC | $31.80 | 2021-2022 | |
| Axonics, INC. | $31.69 | 2022-2023 | Bulkamid |
| Takeda Pharmaceuticals U.S.A., INC. | $22.67 | 2023 | Gammagard |
| Aroa Biosurgery Incorporated | $21.39 | 2023 | |
| Biocompatibles, INC. | $21.07 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $20.44 | 2021 | |
| Glaxosmithkline, LLC. | $18.77 | 2021 | |
| Myriad Genetic Laboratories, INC. | $18.71 | 2024 | Myrisk |
| Radius Health, INC. | $18.66 | 2019 | |
| Aspira Women'S Health INC | $17.73 | 2021 | |
| Lupin INC. | $16.56 | 2019 | |
| Merck Sharp & Dohme LLC | $15.36 | 2021 | |
| Horizon Therapeutics Plc | $14.48 | 2020 | |
| Shield Therapeutics INC | $13.90 | 2023 | Accrufer |
| Tactile Systems Technology INC | $13.42 | 2019 | |
| Minerva Surgical, INC | $12.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Hurst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.